Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

FBIO

Fortress Biotech Inc

Dec 16 • 04:00PM ET

3.51

+0.19 5.72 %

Healthcare • Biotechnology • USA • NASD

Peers: BMRN FOLD PTGX XENE MGTX TGTX QURE ANAB CRSP EDIT

| Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.27	Insider Own	20.13%	Shs Outstand	31.01M	Perf Week	23.59%
Market Cap	108.94M	Forward P/E	-	EPS next Y	-0.60	Insider Trans	0.00%	Shs Float	24.79M	Perf Month	33.97%
Enterprise Value	100.33M	PEG	-	EPS next Q	-0.20	Inst Own	15.19%	Short Float	14.95%	Perf Quarter	2.03%
Income	-5.34M	P/S	1.75	EPS this Y	97.03%	Inst Trans	-1.42%	Short Ratio	4.93	Perf Half Y	91.80%
Sales	62.30M	P/B	1.95	EPS next Y	-650.00%	ROA	2.58%	Short Interest	3.71M	Perf YTD	73.33%
Book/sh	1.80	P/C	1.26	EPS next 5Y	-	ROE	10.35%	52W High	4.20 -16.43%	Perf Year	76.38%
Cash/sh	2.78	P/FCF	-	EPS past 3/5Y	39.06% 24.49%	ROIC	-4.59%	52W Low	1.33 164.91%	Perf 3Y	-65.95%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-5.71% 9.50%	Gross Margin	60.21%	Volatility	7.98% 6.64%	Perf 5Y	-90.37%
Dividend TTM	-	EV/Sales	1.61	EPS Y/Y TTM	94.05%	Oper. Margin	-149.18%	ATR (14)	0.20	Perf 10Y	-92.30%
Dividend Ex-Date	-	Quick Ratio	1.97	Sales Y/Y TTM	-0.32%	Profit Margin	-8.57%	RSI (14)	75.52	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.19	EPS Q/Q	114.54%	SMA20	25.04%	Beta	1.42	Target Price	10.75
Payout	-	Debt/Eq	1.22	Sales Q/Q	20.52%	SMA50	29.61%	Rel Volume	1.52	Prev Close	3.32
Employees	101	LT Debt/Eq	1.08	Earnings	Nov 14 BMO	SMA200	56.31%	Avg Volume	751.61K	Price	3.51
IPO	Nov 17, 2011	Option/Short	Yes / Yes	EPS/Sales Surpr.	126.19% -16.12%	Trades		Volume	1,194,036	Change	5.72%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-15-24	Resumed	ROTH MKM	Buy	$10
Aug-04-22	Initiated	Ladenburg Thalmann	Buy	$6
Oct-02-20	Initiated	The Benchmark Company	Buy	$9
Dec-18-19	Initiated	B. Riley FBR	Buy	$9
Feb-28-18	Initiated	B. Riley FBR, Inc.	Buy	$10
Jul-11-17	Initiated	Rodman & Renshaw	Buy	$11
Mar-22-17	Initiated	JMP Securities	Mkt Outperform
Oct-03-16	Initiated	ROTH Capital	Buy	$9

Dec-15-25 08:00AM	Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission (GlobeNewswire) +13.31%
Dec-10-25 08:30AM	Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology (GlobeNewswire)
Nov-14-25 09:40AM	Fortress Biotech (FBIO) Surpasses Q3 Earnings Estimates (Zacks) +5.22%
08:40AM	Fortress Biotech: Q3 Earnings Snapshot (Associated Press Finance)
08:30AM	Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
05:25PM	Loading…
Nov-12-25 05:25PM	Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Nov-10-25 08:15AM	Kamada (KMDA) Misses Q3 Earnings Estimates (Zacks)
Nov-06-25 05:45PM	Prothena (PRTA) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
Nov-05-25 08:30AM	Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025 (GlobeNewswire)
Nov-04-25 05:15PM	Ultragenyx (RARE) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Oct-30-25 08:15AM	Apellis Pharmaceuticals, Inc. (APLS) Q3 Earnings and Revenues Top Estimates (Zacks)
Oct-24-25 08:30AM	Journey Medical Corporation Reports Combined Emrosi (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference (GlobeNewswire)
Oct-21-25 08:30AM	Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics' Global Phase 3 Trials of Dotinurad for the Treatment of Gout (GlobeNewswire)
Oct-08-25 08:30AM	Journey Medical Corporation to Participate in October 2025 Investor Conferences (GlobeNewswire)
08:05AM	Loading…
Oct-01-25 08:05AM	Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $205 Million Series A Financing (GlobeNewswire) -30.72%
08:00AM	Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101 (GlobeNewswire)
Sep-03-25 08:30AM	Journey Medical Corporation to Participate in September 2025 Investor Conferences (GlobeNewswire)
Sep-02-25 08:30AM	Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire) +15.50%
Aug-18-25 08:30AM	Journey Medical Corporation to Present at the Emerging Growth Conference (GlobeNewswire) +6.13%
Aug-14-25 05:55PM	Fortress Biotech (FBIO) Reports Q2 Loss, Beats Revenue Estimates (Zacks) +8.16%
04:49PM	Fortress Biotech: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-12-25 04:01PM	Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-08-25 08:10AM	Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Aug-07-25 06:25PM	Coherus Oncology (CHRS) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
08:30AM	Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11 (GlobeNewswire)
Aug-05-25 04:01PM	Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025 (GlobeNewswire)
Jul-14-25 08:50AM	Why Fast-paced Mover Fortress Biotech (FBIO) Is a Great Choice for Value Investors (Zacks)
08:30AM	Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi (GlobeNewswire)
09:19AM	Loading…
Jul-10-25 09:19AM	Ultragenyx (RARE) Surges 5.1%: Is This an Indication of Further Gains? (Zacks)
Jun-24-25 08:30AM	Journey Medical to Join Russell 2000 and Russell 3000 Indexes (GlobeNewswire)
Jun-20-25 08:30AM	Journey Medical Corporation Announces Emrosi Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference (GlobeNewswire)
Jun-19-25 08:50AM	Despite Fast-paced Momentum, Fortress Biotech (FBIO) Is Still a Bargain Stock (Zacks)
Jun-09-25 08:30AM	Journey Medical Corporation Announces Emrosi Featured on "The Balancing Act" Airing on Lifetime TV (GlobeNewswire) +6.50%
Jun-03-25 08:50AM	Fortress Biotech (FBIO) Is Attractively Priced Despite Fast-paced Momentum (Zacks)
May-30-25 10:47AM	Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics (GlobeNewswire)
May-16-25 05:50AM	New Strong Sell Stocks for May 16th (Zacks)
May-15-25 05:30PM	Fortress Biotech (FBIO) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +7.23%
04:25PM	Fortress Biotech: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
08:15AM	Precision BioSciences (DTIL) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-14-25 05:15PM	ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-13-25 05:20PM	Exelixis (EXEL) Surpasses Q1 Earnings and Revenue Estimates (Zacks) +5.45%
04:15PM	Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates (GlobeNewswire)
May-08-25 08:50AM	Wave Life Sciences (WVE) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-07-25 04:01PM	Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025 (GlobeNewswire)
08:00AM	Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference (GlobeNewswire)
Apr-01-25 04:01PM	Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer (GlobeNewswire)
Mar-31-25 05:50PM	Fortress Biotech (FBIO) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-28-25 08:30AM	Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates (GlobeNewswire) -6.94%
Mar-26-25 07:39PM	Fortress Biotech, Inc. (FBIO) Q4 2024 Earnings Call Transcript (SeekingAlpha)
04:01PM	Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-25-25 09:04AM	Fortress Biotech Inc (FBIO) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Mar-24-25 08:30AM	Journey Medical Corporation Launches Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea (GlobeNewswire)
Mar-19-25 04:01PM	Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025 (GlobeNewswire)
Mar-17-25 08:55AM	Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform (GlobeNewswire)
Mar-14-25 12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
Mar-12-25 08:30AM	Journey Medical Corporation to Participate in the 37th Annual ROTH Conference (GlobeNewswire)
Mar-09-25 10:06PM	Sun Pharma to Acquire Checkpoint Therapeutics (PR Newswire)
Mar-05-25 04:15PM	Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement (GlobeNewswire)
04:01PM	Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi (DFD-29) to Treat Rosacea (GlobeNewswire)
Mar-04-25 04:01PM	Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida (GlobeNewswire)
Feb-27-25 04:05PM	Mustang Bio Announces Sale of Fixed Assets and Exit of Facility (GlobeNewswire)
Feb-11-25 04:10PM	Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Feb-10-25 08:00AM	Mustang Bio Announces Closing of $8 Million Public Offering (GlobeNewswire)
Feb-06-25 07:00AM	Mustang Bio Announces Pricing of $8 Million Public Offering (GlobeNewswire)
Jan-28-25 08:41AM	Fortress Biotech announces first patient dosed in Phase 2 trial of Triplex (TipRanks)
07:21AM	Fortress doses first subject in Phase II CMV vaccine trial (Clinical Trials Arena)
Jan-27-25 08:30AM	Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT (GlobeNewswire)
Jan-23-25 08:30AM	Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea (GlobeNewswire)
Jan-14-25 08:00AM	Mustang Bio Announces Reverse Stock Split (GlobeNewswire)
Jan-07-25 06:59AM	FDA accepts Sentynls Menkes disease therapy NDA for priority review (Pharmaceutical Technology)
Jan-06-25 08:00AM	Sentynl Therapeutics Announces U.S. FDA Acceptance and Priority Review of New Drug Application for CUTX-101 (Copper Histidinate) Product Candidate for Treatment of Menkes Disease (PR Newswire)
08:00AM	Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease (GlobeNewswire)
Dec-13-24 06:15PM	Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT (cosibelimab-ipdl) (GlobeNewswire)
Nov-14-24 05:04PM	Fortress Biotech: Q3 Earnings Snapshot (Associated Press Finance) -8.92%
04:10PM	Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
04:05PM	Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Nov-12-24 04:30PM	Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates (GlobeNewswire)
04:01PM	Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
08:30AM	Mustang Bio Receives Positive Listing Determination from Nasdaq (GlobeNewswire)
Nov-07-24 08:30AM	Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma (GlobeNewswire)
Nov-04-24 07:00AM	Journey Medical Corporation Announces U.S. FDA Approval of Emrosi (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea (GlobeNewswire) -8.95%
Oct-25-24 01:02PM	Highbridge Capital Management's Strategic Acquisition of Fortress Biotech Shares (GuruFocus.com) +6.94%
08:30AM	Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference (GlobeNewswire)
Oct-24-24 02:10PM	Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds (GlobeNewswire)
Oct-09-24 08:30AM	Avenue Therapeutics to Participate in Maxim Group's 2024 Healthcare Virtual Summit (GlobeNewswire)
Oct-03-24 08:30AM	Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference (GlobeNewswire)
Sep-26-24 08:30AM	Fortress Biotech to Participate in October 2024 Investor Conferences (GlobeNewswire)
Sep-20-24 08:30AM	Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements (GlobeNewswire) -18.75%
Sep-16-24 07:30AM	Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024 (GlobeNewswire)
Sep-09-24 08:30AM	Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference (GlobeNewswire)
Sep-04-24 08:30AM	Fortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -5.08%
08:15AM	Journey Medical Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
08:00AM	Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Sep-03-24 08:30AM	Avenue Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-02-24 08:50AM	Fortress Biotech (FBIO) Shows Fast-paced Momentum But Is Still a Bargain Stock (Zacks)

Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Fortress Biotech, Inc.	10% Owner	May 29 '25	Sale	1.29	100,000	129,000	6,122,249	Jun 03 06:34 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

FBIO

Fortress Biotech Inc

Upgrade your FINVIZ experience